BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27

• Press Releases

  Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

  February 17, 2026

   · 

  3 min read
• Press Releases

  Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

  February 17, 2026

   · 

  18 min read
• Press Releases

  BioCryst to Present at Upcoming March 2026 Investor Conference

  February 17, 2026

   · 

  1 min read
• Press Releases

  Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

  February 17, 2026

   · 

  1 min read
• Press Releases

  EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 17, 2026

  February 17, 2026

   · 

  2 min read
• Press Releases

  Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

  February 17, 2026

   · 

  12 min read
• Press Releases

  NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

  February 17, 2026

   · 

  5 min read
• Press Releases

  Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

  February 17, 2026

   · 

  6 min read
• Press Releases

  AtaiBeckley To Participate in Upcoming March 2026 Investor Conferences

  February 17, 2026

   · 

  1 min read
• Press Releases

  Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

  February 17, 2026

   · 

  23 min read